These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 14577833)

  • 21. Characterization of a preclinical model of simultaneous breast and ovarian cancer progression.
    Ting AY; Kimler BF; Fabian CJ; Petroff BK
    Carcinogenesis; 2007 Jan; 28(1):130-5. PubMed ID: 16891317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetics of ovarian cancer: from the lab to the clinic.
    Asadollahi R; Hyde CA; Zhong XY
    Gynecol Oncol; 2010 Jul; 118(1):81-7. PubMed ID: 20421130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum?
    Jordan SJ; Green AC; Whiteman DC; Webb PM;
    Gynecol Oncol; 2007 Nov; 107(2):223-30. PubMed ID: 17662378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathophysiological dynamics of human ovarian surface epithelial cells in epithelial ovarian carcinogenesis.
    Okamura H; Katabuchi H
    Int Rev Cytol; 2005; 242():1-54. PubMed ID: 15598466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of a carcinogenesis rat model of ovarian preneoplasia and neoplasia.
    Stewart SL; Querec TD; Ochman AR; Gruver BN; Bao R; Babb JS; Wong TS; Koutroukides T; Pinnola AD; Klein-Szanto A; Hamilton TC; Patriotis C
    Cancer Res; 2004 Nov; 64(22):8177-83. PubMed ID: 15548682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ovarian epithelial tumors of low malignant potential: are they precursors of ovarian carcinoma?
    Fukumoto M; Nakayama K
    Pathol Int; 2006 May; 56(5):233-9. PubMed ID: 16669871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis.
    Cai KQ; Yang WL; Capo-Chichi CD; Vanderveer L; Wu H; Godwin AK; Xu XX
    Mol Carcinog; 2007 Feb; 46(2):130-43. PubMed ID: 17131304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-throughput genomic technology in research and clinical management of breast cancer. Molecular signatures of progression from benign epithelium to metastatic breast cancer.
    Rennstam K; Hedenfalk I
    Breast Cancer Res; 2006; 8(4):213. PubMed ID: 16895590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Location of inclusion cysts in mouse ovaries in relation to age, pregnancy, and total ovulation number: implications for ovarian cancer?
    Tan OL; Hurst PR; Fleming JS
    J Pathol; 2005 Mar; 205(4):483-90. PubMed ID: 15685692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteomic analysis of a preneoplastic phenotype in ovarian surface epithelial cells derived from prophylactic oophorectomies.
    He QY; Zhou Y; Wong E; Ehlen TG; Auersperg N; Chiu JF; Wong AS
    Gynecol Oncol; 2005 Jul; 98(1):68-76. PubMed ID: 15913737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Natural history of ovarian adenocarcinomas: from epidemiology to experimentation].
    Hamilton TC; Penault-Llorca F; Dauplat J
    Contracept Fertil Sex; 1998 Nov; 26(11):800-4. PubMed ID: 9864887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular alterations associated with bladder cancer initiation and progression.
    Cordon-Cardo C
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress in biomarker discovery for diagnostic testing in epithelial ovarian cancer.
    Gogoi R; Srinivasan S; Fishman DA
    Expert Rev Mol Diagn; 2006 Jul; 6(4):627-37. PubMed ID: 16824035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies.
    Roland IH; Yang WL; Yang DH; Daly MB; Ozols RF; Hamilton TC; Lynch HT; Godwin AK; Xu XX
    Cancer; 2003 Dec; 98(12):2607-23. PubMed ID: 14669280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer.
    Gotlieb WH; Chetrit A; Menczer J; Hirsh-Yechezkel G; Lubin F; Friedman E; Modan B; Ben-Baruch G;
    Gynecol Oncol; 2005 Jun; 97(3):780-3. PubMed ID: 15893369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Oncogenesis in transgenic mice].
    Shvemberger IN; Ermilov AN
    Tsitologiia; 1994; 36(2):131-47. PubMed ID: 7809963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis.
    Rosen DG; Mercado-Uribe I; Yang G; Bast RC; Amin HM; Lai R; Liu J
    Cancer; 2006 Dec; 107(11):2730-40. PubMed ID: 17063503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patterns of loss of heterozygosity at 10q23.3 and microsatellite instability in endometriosis, atypical endometriosis, and ovarian carcinoma arising in association with endometriosis.
    Ali-Fehmi R; Khalifeh I; Bandyopadhyay S; Lawrence WD; Silva E; Liao D; Sarkar FH; Munkarah AR
    Int J Gynecol Pathol; 2006 Jul; 25(3):223-9. PubMed ID: 16810057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
    Kioi M; Kawakami M; Shimamura T; Husain SR; Puri RK
    Cancer; 2006 Sep; 107(6):1407-18. PubMed ID: 16902988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.